Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q1 Losses Down, R&D Expenses Up

Premium

RXi Pharmaceuticals this week reported lower first-quarter losses despite increased research and development spending on costs associated with the company's preclinical RNAi-based anti-scarring drug candidate RXI-109.

For the three-month period ended March 31, RXi's net loss was about $3.8 million, or $0.19 per share, compared with a year-ago loss of $3.9 million, or $0.24 per share.

R&D expenses climbed to $2.2 million from $1.9 million in the same period a year earlier, reflecting an increase of $442,000 in studies related to RXI-109, as well as consulting activities.

General and administrative costs rose to $3.1 million from $2.5 million, primarily due to an increase in non-cash share-based compensation.

At the end of the first quarter, RXi had cash, cash equivalents, and short-term investments totaling $11.1 million. With the addition of $10 million raised during an April stock offerings, RXi said it expects its resources will be sufficient to fund operations “through at least the first quarter of 2012.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.